CL
LGND icon

Choreo LLC’s Ligand Pharmaceuticals LGND Stock Holding History

Choreo LLC’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$313K Buy
1,570
+166
+12% +$32.8K ﹤0.01% 1227
2025
Q4 		$267K Sell
1,404
-214
-13% -$41.1K ﹤0.01% 1286
2025
Q3 		$287K Buy
+1,618
New +$241K ﹤0.01% 1254

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Choreo LLC's LGND Position: Q1 2026 in Review

Choreo LLC increased its Ligand Pharmaceuticals (LGND) stake by 12% in Q1 2026, buying an estimated $32.8K and bringing the position to 1,570 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #1227.

Choreo LLC first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Choreo LLC held 1,570 shares of Ligand Pharmaceuticals worth $313K as of Q1 2026.
  • Choreo LLC bought 166 Ligand Pharmaceuticals shares in Q1 2026, an estimated $32.8K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Choreo LLC's portfolio in Q1 2026, its #1227 holding.
  • Choreo LLC first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Choreo LLC's 13F filing for Q1 2026, filed 13 May 2026.